This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-06. Anything still debated is marked as such rather than presented as settled.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
It also reduces propranolol clearance and antagonizes the therapeutic effects of antidiabetic agents, levodopa (a Parkinson's medication. This is likely because chlorpromazine antagonizes the D2 receptor which is one of the receptors dopamine, a levodopa metabolite, activates), amphetamines and anticoagulants. It may also interact with anticholinergic drugs such as orphenadrine to produce hypoglycaemia (low blood sugar). Chlorpromazine may also interact with epinephrine (adrenaline) to produce a paradoxical fall in blood pressure. Monoamine oxidase inhibitors (MAOIs) and thiazide diuretics may also accentuate the orthostatic hypotension experienced by those receiving chlorpromazine treatment. Quinidine may interact with chlorpromazine to increase myocardial depression. Likewise, it may also antagonize the effects of clonidine and guanethidine. It also may reduce the seizure threshold and hence a corresponding titration of anticonvulsant treatments should be considered. Prochlorperazine and desferrioxamine may also interact with chlorpromazine to produce transient metabolic encephalopathy. Other drugs that prolong the QT interval, such as quinidine, verapamil, amiodarone, sotalol and methadone, may also interact with chlorpromazine to produce additive QT interval prolongation. Chlorpromazine is a serotonin 5-HT2A receptor antagonist and has been found to reduce the hallucinogenic effects of serotonergic psychedelics like LSD.
== Production and processing == Producing a biomaterial from raw silk generally proceeds through three stages: the fibroin is purified, dissolved into a workable solution, then shaped and stabilised into a final form. Cocoons are boiled in a mild alkaline solution, usually sodium carbonate, which removes the sericin. The degummed fibres are then dissolved, most often in concentrated lithium bromide, a salt concentrated enough to disrupt the hydrogen bonds holding the beta-sheet domains together. Dialysis against water removes the salt and leaves an aqueous fibroin solution, the common precursor for nearly everything that follows. A single solution yields a striking variety of forms. Dried as a thin layer on a surface, it produces films and coatings used in optics, in sensors and to modify the surfaces of implants. When the protein assembles into a soft, water-swollen network—a transition driven by changes in pH or temperature, by sonication or by an applied electric field—the result is a hydrogel. Freeze-drying, or casting the protein around salt crystals or gas bubbles, produces porous sponges and scaffolds whose interconnected pores allow cells to grow in three dimensions. Drawing the solution through a high electric field spins it into fine fibres, a technique known as electrospinning, which yields non-woven mats resembling the natural network surrounding cells. The same solution can also be formed into microspheres and nanoparticles for carrying and releasing drugs.
Nuclear fission is a reaction in which the nucleus of an atom splits into two or more smaller nuclei. The fission process often produces neutrons and gamma rays, and releases a very large amount of energy even by the energetic standards of radioactive decay. The free energy released by the fission of one uranium-235 atom is about 100 million times the energy released by burning one carbon atom in air to produce CO2. Nuclear fission was discovered by chemists Otto Hahn and Fritz Strassmann and physicists Lise Meitner and Otto Robert Frisch. Hahn and Strassmann proved that a fission reaction had taken place on 19 December 1938, and Meitner and her nephew Frisch explained it theoretically in January 1939. Frisch named the process "fission" by analogy with biological fission of living cells. In their second publication on nuclear fission in February 1939, Hahn and Strassmann predicted the existence and liberation of additional neutrons during the fission process, opening up the possibility of a nuclear chain reaction by assembling a critical mass of fissile material. For heavy nuclides, it is an exothermic reaction which releases large amounts of energy both as electromagnetic radiation and as kinetic energy of the fragments (heating the bulk material where fission takes place). Like nuclear fusion, for fission to produce energy, the total binding energy of the resulting elements must be greater than that of the starting element. The fission barrier must also be overcome.
The United States investigated ricin for its military potential during World War I. At that time it was being considered for use either as a toxic dust or as a coating for bullets and shrapnel. The dust cloud concept could not be adequately developed, and the coated bullet/shrapnel concept would violate the Hague Convention of 1899 (adopted in U.S. law at 32 Stat. 1903), specifically Annex §2, Ch.1, Article 23, stating "... it is especially prohibited ... [t]o employ poison or poisoned arms". In 'Ricin and Abrin', Manashi Bagchi, Shirley Zafra-Stone, Francis C. Lau, and Debasis Bagchi wrote that during World War II the United States and Canada studied ricin in cluster bombs. Though there were plans for mass production and several field trials with different bomblet concepts, the end conclusion was that it was no more economical than using phosgene. This conclusion was based on comparison of the final weapons, rather than ricin's toxicity (LCt50 ~10 mg/min·m3). Ricin was given the military symbol W or later WA. Interest in it continued for a short period after World War II, but soon subsided when the US Army Chemical Corps began a program to weaponize sarin. The Soviet Union possessed weaponized ricin. The KGB developed weapons using ricin which were used outside the Soviet bloc, most famously in the Markov assassination.
== Narcotics == Narcotics are opium, its derivatives, and their semi-synthetic substitutes. They depressants that slows down nervous system activity, and are prescribed to treat pain, suppress coughs, cure diarrhea, and induce sleep. Examples include buprenorphine, dextromoramide, diamorphine (heroin), fentanyl, hydrocodone (Vicodin), hydromorphone, pethidine, methadone, morphine, nicomorphine, oxycodone (OxyContin), oxymorphone, pentazocine, and tramadol.
Sources: en.wikipedia.org
British Military History – Including British Indian Army during WW2 The Indian Army 1900–1939. Archived 5 July 2019 at the Wayback Machine. The Indian Army Archived 24 March 2023 at the Wayback Machine – talk by Rob Lyman on WWII Indian Army at We Have Ways Festival
The farming of fish is the most common form of aquaculture. It involves raising fish commercially in tanks, fish ponds, or ocean enclosures, usually for food. A facility that releases juvenile fish into the wild for recreational fishing or to supplement a species' natural numbers is generally referred to as a fish hatchery. Worldwide, the most important fish species used in fish farming are, in order, carp, salmon, tilapia, and catfish. In the Mediterranean, young bluefin tuna are netted at sea and towed slowly towards the shore. They are then interned in offshore pens (sometimes made from floating HDPE pipe) where they are further grown for the market. In 2009, researchers in Australia managed for the first time to coax southern bluefin tuna to breed in landlocked tanks. Southern bluefin tuna are also caught in the wild and fattened in grow-out sea cages in southern Spencer Gulf, South Australia. A similar process is used in the salmon-farming section of this industry; juveniles are taken from hatcheries and a variety of methods are used to aid them in their maturation. For example, as stated above, some of the most important fish species in the industry, salmon, can be grown using a cage system. This is done by having netted cages, preferably in open water that has a strong flow, and feeding the salmon a special food mixture that aids their growth. This process allows for year-round growth of the fish, thus a higher harvest during the correct seasons. An additional method, known sometimes as sea ranching, has also been used within the industry.
Functional amyloid in Homo sapiens: Intralumenal domain of melanocyte protein PMEL Peptide/protein hormones stored as amyloids within endocrine secretory granules in the pituitary gland Receptor-interacting serine/threonine-protein kinase 1/3 (RIP1/RIP3) Fragments of prostatic acid phosphatase and semenogelins Functional amyloid in other organisms: Curli fibrils produced by E. coli, Salmonella, and a few other members of the Enterobacteriales (Csg). The genetic elements (operons) encoding the curli system are phylogenetic widespread and can be found in at least four bacterial phyla. This suggest that many more bacteria may express curli fibrils. GvpA, forming the walls of particular Gas vesicles, i.e. the buoyancy organelles of aquatic archaea and eubacteria Fap fibrils in various species of Pseudomonas Chaplins from Streptomyces coelicolor Spidroin from Trichonephila edulis (spider) (Spider silk) Hydrophobins from Neurospora crassa and other fungi Fungal cell adhesion proteins forming cell surface amyloid regions with greatly increased binding strength Environmental biofilms according to staining with amyloid specific dyes and antibodies. Tubular sheaths encasing Methanosaeta thermophila filaments Functional amyloid acting as prions Several yeast prions are based on an infectious amyloid, e.g. [PSI+] (Sup35p); [URE3] (Ure2p); [PIN+] or [RNQ+] (Rnq1p); [SWI1+] (Swi1p) and [OCT8+] (Cyc8p) Prion HET-s from Podospora anserina Neuron-specific isoform of CPEB from Aplysia californica (marine snail)
Certain antidepressant medications act to raise noradrenaline, such as serotonin-norepinephrine reuptake inhibitors (SNRIs), norepinephrine-dopamine reuptake inhibitors (NDRIs), norepinephrine reuptake inhibitors (NRIs or NERIs) and the tricyclic antidepressants (TCAs). The mechanism by which these medications work is that the reuptake inhibitors prevent the reuptake of serotonin and norepinephrine by the presynaptic neuron, paralyzing the normal function of the NET. At the same time, higher levels of 5-HT are maintained in the synapse increasing the concentrations of the latter neurotransmitters. Since the noradrenaline transporter is responsible for most of the dopamine clearance in the prefrontal cortex, SNRIs block reuptake of dopamine too, accumulating the dopamine in the synapse. However, DAT, the primary way dopamine is transported out of the cell, can work to decrease dopamine concentration in the synapse when the NET is blocked. For many years, the number one choice in treating mood disorders like depression was through administration of TCAs, such as desipramine (Norpramin), nortriptyline (Arentyl, Pamelor), protriptyline (Vivactil), and amoxapine (Asendin). SSRIs, which mainly regulate serotonin, subsequently replaced tricyclics as the primary treatment option for depression because of their better tolerability and lower incidence of adverse effects.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
Reverse-phase liquid chromatography and mass spectrometry are the most common techniques. Chromatography assesses purity, while mass spectrometry confirms molecular identity. Additional methods may be applied when higher confidence is required.